共 29 条
[1]
Ambrozi, Birkmayer, Danielczyk, Neumayer, Riederer, Biochemische Aspekte des menschlichen Verhaltens, Wr. Z. Nervenheilk., 31, (1973)
[2]
Ambrozi, Birkmayer, Riederer, Youdim, L-Dopa and (−) Deprenyl in the treatment of Parkinson's disease, Brit. J. Pharmacol., 58, 3, (1976)
[3]
Barbeau, Advanc. Neurology, Treatment of Parkinson's disease with L-Dopa and R04-4602
[4]
review and present status, 2, (1973)
[5]
Bartholini, Prada, Pletscher, Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase, J. Pharm. Pharmacol., 20, (1968)
[6]
Bernheimer, Birkmayer, Hornykiewicz, Jellinger, Seitelberger, Brain dopamine and the syndromes of Parkinson and Huntington, J. Neurol. Sci., 20, (1973)
[7]
Birkmayer, Mentasti, Weitere experimentelle Untersuchungen über den Catechol-aminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson und Chorea-Syndrom), Arch. Psychiat. Nervenkr., 210, (1967)
[8]
Birkmayer, Neumayer, Die moderne medikamentöse Behandlung des Parkinsonismus, Z. Neurol., 202, (1972)
[9]
Birkmayer, Neumayer, Die Behandlung der Dopa-Psychosen mit L-Tryptophan, Nervenarzt, 43, (1972)
[10]
Birkmayer, Danielczyk, Neumayer, Riederer, L-Dopa level in plasma, primary condition for the kinetic effect, J. Neural Transm., 34, (1973)